Notice of Interim Results

London, UK - 1 September 2021: Oxford Biomedica plc (LSE:OXB), a leading gene and cell therapy group, will be announcing its interim results for the six months ended 30 June 2021 on Wednesday 22 September 2021.

A briefing for analysts will be held at 13:00 BST / 08:00 EST on the day of the results at 85 Gresham Street, London EC2V 7NQ. There will also be a live conference call with a Q&A session and live webcast. The presentation and webcast details will be made available on the Group's website at www.oxb.com. A replay of the presentation will be made available shortly afterwards.

- Ends -

Enquiries:       

Oxford Biomedica plc: T: +44 (0)1865 783 000 / E: [email protected]

John Dawson, Chief Executive Officer

Stuart Paynter, Chief Financial Officer

Catherine Isted, Head of Corporate Development & IR
Sophia Bolhassan, Director of IR

Consilium Strategic Communications: T: +44 (0)20 3709 5700

Mary-Jane Elliott / Matthew Neal            

About Oxford Biomedica

Oxford Biomedica (LSE:OXB) is a leading, fully integrated, cell and gene therapy group focused on developing life changing treatments for serious diseases. Oxford Biomedica and its subsidiaries (the "Group") have built a sector leading lentiviral vector delivery platform (LentiVector®), which the Group leverages to develop in vivo and ex vivo products both in-house and with partners. The Group has created a valuable proprietary portfolio of gene and cell therapy product candidates in the areas of oncology, ophthalmology, CNS disorders and liver diseases. The Group has also entered into a number of partnerships, including with Novartis, Bristol Myers Squibb, Sio Gene Therapies, Orchard Therapeutics, Santen, Beam Therapeutics, Boehringer Ingelheim, the UK Cystic Fibrosis Gene Therapy Consortium and Imperial Innovations, through which it has long-term economic interests in other potential gene and cell therapy products. Additionally the group has signed a 3 year master supply and development agreement with AstraZeneca for large-scale manufacturing of the adenoviral based COVID-19 vaccine, AZD1222. Oxford Biomedica is based across several locations in Oxfordshire, UK and employs more than 670 people. Further information is available at www.oxb.com